# NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

> **NCT01954576** · NA · TERMINATED · sponsor: **University of Florida** · enrollment: 21 (actual)

## Conditions studied

- Glioblastoma
- Brain Neoplasms

## Interventions

- **DEVICE:** NovoTTF-100A
- **PROCEDURE:** Quality-of-life assessment
- **GENETIC:** Laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01954576
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10-10
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-05-14
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Poor accrual; Avastin refractory patients not feasible given treatment paradigm in these patients.
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954576, "NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01954576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*